Naimish Patel
Chief Medical OfficerDr. Naimish Patel, M.D., C.M., has been Non-Executive Director of Agomab Therapeutics NV since September 11, 2026. He has been the Chief Medical Officer of CRISPR Therapeutics since May 28, 2024. Dr. Patel was Head of Global Development, Immunology & Inflammation Therapeutic Area at Sanofi. Dr. Patel has been Member of Clinical Advisory Board at Proteostasis Therapeutics, Inc. since September 28, 2016. Dr. Patel joined AstraZeneca in September 2013 and has led early clinical development teams, as well as pre-clinical development teams identifying and developing compounds from target identification to Phase 1 to Phase 2b. Prior to joining AstraZeneca, Dr. Patel served as Associate Medical Director in the Clinical Medical Director Group in CF for Vertex Pharmaceuticals, where he led an early-phase Cystic Fibrosis Transmembrane conductance Regulator corrector program, the biomarkers task force and a Phase 3 study program. Dr. Patel is an Attending Physician in the Intensive Care Unit and Pulmonary Outpatient Services at Beth Israel Deaconess Medical Center. Dr. Patel earned his BS degree in mechanical engineering from Massachusetts Institute of Technology (1989-1993) and received a Doctor of Medicine (1993-1997) and M.D. of Surgery from McGill University Faculty of Medicine. Dr. Patel also completed a fellowship in pulmonary and critical care medicine at Harvard Medical School.
Positions
- Company NameCRISPR Therapeutics AGStock CodeCRSPPositionChief Medical OfficerColleagues
- SKSamarth KulkarniCEO & Chairman
- JRJames R. KasingerGeneral Counsel & Secretary
- RYRaju Yashaswi PrasadExecutive Officer
- SFShaun FoyCo-Founder
- EMEmmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board Member
- CCCraig C. MelloScientific Founder & Advisory Board Member
- MPMatthew PorteusScientific Founder & Advisory Board Member
- DGDaniel G. AndersonScientific Founder & Advisory Board Member
